Search Results - "SYVÄNNE, M"

Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer by Hedman, M, Muona, K, Hedman, A, Kivelä, A, Syvänne, M, Eränen, J, Rantala, A, Stjernvall, J, Nieminen, M S, Hartikainen, J, Ylä-Herttuala, S

“…Vascular endothelial growth factor (VEGF) has been shown to stimulate angiogenesis and myocardial perfusion. The short-term safety of VEGF gene therapy is…”
Get full text

Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease by Mero, N., Malmström, R., Steiner, G., Taskinen, M.-R., Syvänne, M.

“…The aim of the present cross-sectional angiographic study was to examine if there is a relationship between the severity of CAD and postprandial lipemia in…”
Get full text

Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by Gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol by FRICK, M. H, SYVÄNNE, M, NIEMINEN, M. S, KAUMA, H, MAJAHALME, S, VIRTANEN, V, KESÄNIEMI, Y. A, PASTERNACK, A, TASKINEN, M.-R

“…Background Studies have shown that treatment of hyperlipidemia, especially lowering of plasma LDL levels, retards the progression of coronary atherosclerosis…”
Get full text

Impaired endothelium-dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants by MAKIMATTILA, S, LIU, M.-L, YKI-JARVINEN, H, VAKKILAINEN, J, SCHLENZKA, A, LAHDENPERA, S, SYVANNE, M, MANTYSAARI, M, SUMMANEN, P, BERGHOLM, R, TASKINEN, M.-R

“…Impaired endothelium-dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants. S Mäkimattila , M L Liu , J Vakkilainen ,…”
Get full text

High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease by Syvänne, M, Ahola, M, Lahdenperä, S, Kahri, J, Kuusi, T, Virtanen, K S, Taskinen, M R

“…High density lipoprotein (HDL) subfractions (2b, 2a, 3a, 3b, and 3c) separated by gradient gel electrophoresis (GGE) and defined by Gaussian summation…”
Get full text

Postprandial lipid metabolism in diabetes by Mero, Niina, Syvänne, Mikko, Taskinen, Marja-Riitta

“…Postprandial lipemia is an inherent feature of diabetic dyslipidemia and highly prevalent in diabetic patients even with normal fasting triglyceride…”
Get full text

The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study by Humphries, Steve E, Luong, Le-Anh, Talmud, Philippa J, Frick, M.Heikki, Antero Kesäniemi, Y, Pasternack, Amos, Taskinen, Marja-Riitta, Syvänne, Mikko

“…The relationship between the 5A/6A stromelysin-1 promoter polymorphism and progression of angiographically determined coronary artery disease (CAD) has been…”
Get full text

Systolic and diastolic heart failure--diagnostic and therapeutic dilemmas by Syvänne, M

“…Clinical suspicion of congestive heart failure (CHF) always requires a careful diagnostic workup. This comprises the verification of the presence of CHF (in…”
Get more information

Determinants of postprandial lipemia in men with coronary artery disease and low levels of HDL cholesterol by Syvanne, M, Talmud, P.J, Humphries, S.E, Fisher, R.M, Rosseneu, M, Hilden, H, Taskinen, M.R

“…We studied the determinants of postprandial lipemia in 49 post-coronary-bypass men with low HDL cholesterol (greater than or equal to 1.1 mmol/l at screening)…”
Get full text

Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol by SYVÄNNE, M, NIEMINEN, M. S, FRICK, M. H, KAUMA, H, MAJAHALME, S, VIRTANEN, V, KESÄNIEMI, Y. A, PASTERNACK, A, EHNHOLM, C, TASKINEN, M.-R

“…Lipid-lowering secondary-prevention trials of coronary artery disease (CAD) have implicated triglyceride-rich lipoproteins as the main determinants of…”
Get full text

Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia by Gerstein, Hertzel C, Bosch, Jackie, Dagenais, Gilles R, Díaz, Rafael, Jung, Hyejung, Maggioni, Aldo P, Pogue, Janice, Probstfield, Jeffrey, Ramachandran, Ambady, Riddle, Matthew C, Rydén, Lars E, Yusuf, Salim

“…In this study with a 2-by-2 factorial design, patients with cardiovascular risk factors and dysglycemia or type 2 diabetes received insulin glargine or…”
Get full text

n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia by Bosch, Jackie, Gerstein, Hertzel C, Dagenais, Gilles R, Díaz, Rafael, Dyal, Leanne, Jung, Hyejung, Maggiono, Aldo P, Probstfield, Jeffrey, Ramachandran, Ambady, Riddle, Matthew C, Rydén, Lars E, Yusuf, Salim

“…Participants with impaired fasting glucose who were at risk for cardiovascular events were assigned to receive daily n−3 fatty acids or placebo and to receive…”
Get full text

HDLs containing apolipoproteins A-I and A-II (LpA-I:A-II) as markers of coronary artery disease in men with non-insulin-dependent diabetes mellitus by SYVÄNNE, M, KAHRI, J, VIRTANEN, K. S, TASKINEN, M.-R

“…Abnormalities in HDL and an increased risk of coronary artery disease (CAD) coexist in non-insulin-dependent diabetes mellitus (NIDDM). HDLs can be separated…”
Get full text

Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus by SYVÄNNE, M, VUORINEN-MARKKOLA, H, HILDEN, H, TASKINEN, M.-R

“…The effect of gemfibrozil on postprandial lipoprotein metabolism was investigated in a 12-week, randomized, double-blind, placebo-controlled trial in 20…”
Get full text

Significance of graft occlusion and coronary atherosclerosis 5 years after coronary artery bypass grafting. A quantitative angiographic study with serial exercise testing by Korpilahti, K., Engblom, E., Hämäläinen, H., Syvänne, M., Hietanen, E., Arstila, M., Puukka, P., Rönnemaa, T.

“…  Korpilahti K, Engblom E, Hämäläinen H, Syvänne M, Hietanen E, Arstila M, Puukka P, Rönnemaa T (Central Hospital of Vaasa, Turku University Central Hospital,…”
Get full text

Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus by Syvänne, M, Taskinen, M R

Get more information

Angiographic changes in saphenous vein grafts and atherosclerosis risk factors. A 5-year study with serial measurements of serum lipids and lipoproteins by Korpilahti, K, Engblom, E, Syvänne, M, Hämäläinen, H, Puukka, P, Vänttinen, E, Rönnemaa, T

“…The association between cardiovascular risk factors and stenosis or occlusion of saphenous vein grafts was analysed in a prospective 5-year study of 176…”
Get more information

Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy by Hamsten, A, Syvänne, M, Silveira, A, Luong, L A, Nieminen, M S, Humphries, S, Frick, M H, Taskinen, M R

“…Impaired fibrinolytic function, mainly due to increased plasma plasminogen activator inhibitor-1 (PAI-1) activity, is common in patients with manifest coronary…”
Get more information

Plasma cholesteryl ester transfer protein activity in non-insulin-dependent diabetic patients with and without coronary artery disease by Kahri, J, Syvänne, M, Taskinen, M R

“…The present study was designed to evaluate the potential role of plasma cholesteryl ester transfer protein (CETP) activity in the regulation of high-density…”
Get more information

Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE) by Punthakee, Z, Gerstein, HC, Bosch, J, Tyrwhitt, J, Jung, H, Lee, SF, Lonn, E, Marsden, T, McKelvie, R, McQueen, MJ, Morillo, CA, Yusuf, S, Dagenais, GR, Diaz, R, Maggioni, AP, Probstfield, J, Ramachandran, A, Riddle, MC, Ryden, LE, Badings, EA, Birkeland, KI, Cardona, E, Commerford, P, Davies, M, Fodor, JG, Gomis, R, Hanefeld, M, Hildebrandt, P, Kacerovsky-Bielesz, G, Keltai, M, Lanas, F, Lewis, BS, Lopez-Jaramillo, P, Marin-Neto, J, Marre, M, Mendoza, I, Pan, CY, Pirags, V, Rosenstock, J, Spinas, GA, Sreenan, S, Syvanne, M, Yale, JF

“…The Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial reported neutral effects of insulin glargine on cardiovascular outcomes and cancers and…”
Get full text